Grŵp Strategaeth Meddyginiaethau Cymru Gyfan
All Wales Medicines Strategy Group

Final Appraisal Recommendation

Advice No: 0518 – March 2018

Levodopa-carbidopa intestinal gel (Duodopa®) 20 mg/ml levodopa and 5 mg/ml carbidopa monohydrate

Resubmission AbbVie Ltd

Recommendation of AWMSG

Levodopa-carbidopa intestinal gel (Duodopa®) is recommended as an option for restricted use within NHS Wales.

Levodopa-carbidopa intestinal gel (Duodopa®) should be restricted for use in the following subpopulation within its licensed indication for the treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results:

- **Patients not eligible for deep brain stimulation.**

Levodopa-carbidopa intestinal gel (Duodopa®) is not recommended for use within NHS Wales outside of this subpopulation.

This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.

Additional note(s):

- AWMSG considered that levodopa-carbidopa intestinal gel (Duodopa®) satisfied the AWMSG criteria for appraising orphan and ultra-orphan medicines and medicines developed specifically for rare disease

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 3397), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue	AbbVie Ltd
Date of first issue	March 2018
Last reviewed	March 2021